Understanding and Overcoming Resistance to Selective FGFR inhibitors Across FGFR2-Driven Malignancies.
Francesco FacchinettiYohann LoriotFloriane BrayeDamien VasseurRastislav BahledaLudovic BigotRémy BarbéCatline NobreDavid CombarelStefan MichielsAntoine ItalianoCristina SmolenschiLambros TselikasJean Yves ScoazecSantiago Ponce-AixBenjamin BesseFabrice AndreKen A OlaussenAntoine HollebecqueLuc FribouletPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
At progression to FGFR inhibitors, FGFR2-driven malignancies are characterized by high intra- and inter-patient molecular heterogeneity, particularly in cholangiocarcinoma. Resistance to FGFR inhibitors can be overcome by sequential, molecularly-oriented treatment strategies across FGFR2-driven tumors.
Keyphrases